COVID-19, COVID-19 Vaccine, Lyme Disease
Conditions
Brief summary
A cross-sectional descriptive survey of the BOLD for individuals after having been ill with COVID-19 or have taken the COVID-19 vaccine will be compared with that of individuals who have neither been ill with COVID-19 nor taken the COVID-19 vaccine. Individuals who have both been ill and taken the COVID-19 vaccine will be compared to identify any additive risk factors.
Detailed description
Primary research question: 1\. Will the BOLD be worse for individuals who have taken the COVID-19 vaccine? Secondary research questions: 1. Will the BOLD be worse for individuals who have been ill with COVID-19? 2. What factors affect the BOLD in individuals a) after having been ill with COVID-19, and b) in those who have taken the COVID-19 vaccine? Do they differ? 3. If BOLD risk factors specific to either the COVID-19 vaccine or having been ill with COVID-19 are found, are they additive in people who have experienced both? 4. What is the prevalence of hesitancy in the Lyme disease community to the COVID-19 vaccine? 5. What is the severity of symptoms most likely to predict functional problems in individuals with Lyme disease who have been ill with COVID-19 or taken the COVID-19 vaccine?
Interventions
A cross-sectional descriptive survey of the Burden of Lyme disease for individual with a history of Lyme disease who contract COVID-19 or are vaccinated against COVID-19
Sponsors
Dr. Daniel Cameron & Associates
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Inclusion criteria
* ≥12 years old * a self-report of having been diagnosed with Lyme disease.
Exclusion criteria
* There are no
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Burden of Illness using a General Symptom Questionnaire-30 questionnaire (GSQ-30) | 7/21 to 7/23 | Cross sectional |
Countries
United States
Contacts
Primary ContactDaniel Cameron, MD, MPH
Outcome results
None listed